RRML - Evaluation of thrombin generation in classical Philadelphia-negative myeloproliferative neoplasms

ISSN online: 2284-5623

ISSN-L: 1841-6624

Impact factor (2019): 0.945

Rejection rate (2020): 75%

Română English

Clarivate analytics (ISI) Impact factor

Advanced search

Top 10 downloaded articles
- June 2021 -
The evaluation of a diagnostic... 47
Prognostic value of serum lact... 20
The possibility of clinical us... 10
Romanian Review of Laboratory ... 9
Prevalence of ∆F508 cystic f... 9
Predictors associated with inc... 8
Essentials in the diagnosis of... 8
Platelets and Infections... 7
Evaluation of Plasma AA/DHA+EP... 7
Pseudohyponatremia and falsely... 7

Log in

Concept, Design & Programming
Dr. Adrian Man

Nr. 24(3)/2016 DOI:10.1515/rrlm-2016-0026

Research article

Evaluation of thrombin generation in classical Philadelphia-negative myeloproliferative neoplasms

Ariela Ligia Olteanu, Romeo-Gabriel Mihăilă, Manuela Mihalache

Correspondence should be addressed to: Ariela Ligia Olteanu


Introduction: Patients with Philadelphia-negative chronic myeloproliferative neoplasms (Ph-MPN), polycytemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF), are prone to develop thrombotic events. We aimed to investigate the coagulation status in their plasma using thrombin generation assay (TGA), a functional global assay, on Ceveron® Alpha. Materials and methods: The samples were collected from 89 consecutive Ph-negative MPN patients and from 78 controls into K2EDTA and CTAD tubes for blood cell counts, TGA and coagulation screening tests. Thrombin generation was analysed in platelet-poor plasma using Technothrombin® TGA assay kit. Results: We found a significantly increased peak thrombin generation (p=0.049) and velocity index (VI) (p=0.012) in patients in comparison with controls, especially in ET patients, and a significantly higher values for peak thrombin (p=0.043) and VI (p=0.042) in patients receiving anagrelide in comparison with those treated with hydroxyurea. We also noticed an inverse correlation between the length of cytoreductive therapy and TGA parameters, (peak thrombin R=-0.25, p=0.018, AUC R=-0.257, p=0.015, and VI R=-0.21, p=0.048). Conclusion: Our results suggest that Ph-MPN patients, and especially those with ET, are predisposed to thrombotic events due to their higher peak thrombin and VI values and their risk may decreases as treatment is longer. Patients treated with hydroxyurea generate less thrombin and could be less prone to develop thrombotic events in comparison with those treated with anagrelide.

Keywords: thrombin generation, polycythemia vera, essential thrombocythemia, idiopatic myelofibrosis, thrombosis

Received: 4.3.2016
Accepted: 2.7.2016
Published: 25.7.2016

  PDF Download full text PDF
(368 KB)
How to cite
Olteanu AL, Mihăilă RG, Mihalache M. Evaluation of thrombin generation in classical Philadelphia-negative myeloproliferative neoplasms. Rev Romana Med Lab. 2016;24(3):279-89. DOI:10.1515/rrlm-2016-0026